UNSPSC 51172427: Atropine/hyoscyamine/kaolin/pectin/scopolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.

UNSPSC 51172427 Atropine/hyoscyamine/kaolin/pectin/scopolamine is a Commodity code that nominally encompasses specific pharmaceutical active ingredients, yet recent state and local solicitations show little direct activity tied to this code's precise chemical composition. The three most recent opportunities tagged to this code span offender drug testing specimen collection and lab services, a state pharmacy benefit exploration for direct-to-manufacturer contracting, and a multistate cooperative purchasing vehicle for generic pharmaceuticals and over-the-counter products—none of which center on the atropine/hyoscyamine/kaolin/pectin/scopolamine combination or its individual components as primary procurement objects. Issuing bodies include a Texas county community supervision department, a state health and human services commission, and a multistate cooperative purchasing alliance administered by Minnesota, suggesting that when this code does appear in state and local procurement, it surfaces in criminal-justice offender management, health agency pharmacy benefit programs, and cooperative purchasing consortia rather than in targeted acquisitions of these specific compounds.

Geographic activity centers on Texas and Minnesota based on recent postings, though the Minnesota opportunity spans multiple participating states including Oregon. A representative opportunity is Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, valued at $600,000 over two years with optional renewals—a contract requiring lab certification and immunoassay screening with confirmation testing capacity, not procurement of the active ingredients themselves. A second example is Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, open to manufacturers willing to supply through authorized wholesalers across state and local facilities. The code appears to show limited direct relevance to recent solicitations; firms targeting this Commodity code should verify whether opportunities are genuinely acquiring the specified pharmaceutical components or have been miscoded in the source system.